PT  - JOURNAL ARTICLE
AU  - Conte, Luana
AU  - Amodeo, Ilaria
AU  - De Nunzio, Giorgio
AU  - Raffaeli, Genny
AU  - Borzani, Irene
AU  - Persico, Nicola
AU  - Griggio, Alice
AU  - Como, Giuseppe
AU  - Colnaghi, Mariarosa
AU  - Fumagalli, Monica
AU  - Cascio, Donato
AU  - Cavallaro, Giacomo
TI  - A machine learning approach to predict mortality and pulmonary hypertension severity in newborns with congenital diaphragmatic hernia
AID  - 10.1101/2024.07.25.24311009
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.07.25.24311009
4099  - http://medrxiv.org/content/early/2024/07/26/2024.07.25.24311009.short
4100  - http://medrxiv.org/content/early/2024/07/26/2024.07.25.24311009.full
AB  - Prenatal prediction of postnatal outcomes in newborns with congenital diaphragmatic hernia (CDH) remains challenging, especially for mortality and neonatal persistent pulmonary hypertension (PPHN). Despite the increasing utilization of advanced artificial intelligence (AI) technologies in the neonatal field, this study is pioneering in exploring AI methodologies in the context of CDH. It represents an initial attempt to implement a Machine Learning (ML) system to predict postnatal mortality and PPHN severity, using prenatal and early postnatal data as input variables. We enrolled 50 patients with isolated left-sided CDH from singleton pregnancies and retrospectively collected clinical and imaging variables from fetal ultrasound (US) and shape features extracted from magnetic resonance imaging (MRI), combined with gestational age and birth weight. A supervised ML model for predicting mortality and PPHN severity was developed, achieving good accuracy (88% for mortality prediction and 82% for PPHN) and sensitivity (95% for mortality and 85% for PPHN). The area under the curve (AUC) of the ROC curve was 0.88 for mortality and 0.82 for PPHN predictions. Our results may lead to novel AI applications in the neonatal field, focusing on predicting postnatal outcomes based on prenatal data, ultimately improving prognostic assessments and intervention strategies for such a complex disease.Clinical Trial Registration The trial was registered at ClinicalTrials.gov with Identifier NCT04609163What is Known prenatal prediction of postnatal mortality and severity of pulmonary hypertension in CDH newborns remains challenging and largely based on imaging through the volumetric assessment of fetal lungs.What is New developing a ML system for predicting PPHN severity and mortality risk based on the integrated assessment of prenatal and early postnatal variables is feasible, with good accuracy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study was registered on ClinicalTrials.gov with the identifier NCT04609163.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The current study adhered to the principles of good clinical practice and followed the guidelines of the Helsinki Declaration. It received approval from the local ethics committee (Milan Area 2, Italy) with approval number/ID 800_2020bis. However, considering its retrospective design, the ethics committee waived the need for informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.